KOL Insight - Non-Hodgkin Lymphoma

This comprehensive report delves into the evolving landscape of targeted therapies for Non-Hodgkin Lymphoma (NHL), providing you with in-depth insights into current and future treatment pathways. It explores the comparative efficacy and safety profiles of key marketed drug classes, including CAR T-cell therapies, bispecific antibodies, antibody-drug conjugates, monoclonal antibodies, and BTK inhibitors. The report also examines the potential impact of novel therapies in mid-to-late stage clinical development and highlights significant ongoing clinical trials that could shape future prescribing trends. This report offers a nuanced understanding of how treatment paradigms for NHL are likely to evolve over the next few years, identifying both challenges and opportunities in the field.

Key Questions Answered:

• 1. CAR T-cell therapies are now a mainstay in DLBCL, FL and MCL in many localities, but how is their use expected to evolve in the foreseeable future?
• 2. With T-cell-engaging bispecific antibodies from Roche and AbbVie/Genmab (and also Regeneron in Europe) now approved for FL, how do KOLs expect the treatment algorithm to evolve?
• 3. With Roche's Columvi now approved in Europe (based on STARGLO), and several other trials of bispecifics in second-line DLBCL underway, could this modality become a standard of care in this setting?
• 4. How is Regeneron's bispecific antibody Ordspono perceived by NHL specialists, and could it still find a role in an increasingly competitive market despite its relatively late entry?
• 5. What are KOL expectations for Merck & Co.'s pipeline anti-ROR1 antibody-drug conjugate zilovertamab vedotin in the treatment of DLBCL?
• 6. With the recent FDA and EMA extended approval for AstraZeneca's Calquence to include first-line MCL and the MANGROVE trial of BeiGene's Brukinsa underway, how do the experts weigh up the prospects for BTK inhibitors in this frontline setting?
• 7. How might the treatment landscape for B-cell NHL evolve in the coming years?

Key Brands:

Partial List of Participating Experts:

• Director, Lymphoma Division, Levine Cancer Institute, USA
• Medical Director of Hematology Research, Sarah Cannon Research, USA
• Professor of Medicine and Chief of Lymphoma Section at Division of Hematology, University of Miami, USA
• Consultant Haematologist specialising in lymphoid malignancies, Oxford University Hospitals NHS Foundation Trust, UK
• Medical Director and Senior Practitioner in onco-hematology, Gustave Roussy Institute, France
• Professor, Service d'Hematologie et de Therapie Cellulaire, CHU Estaing, Universite Clermont Auvergne, France

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.